Biocon Biologics Inc. (United States)

Biocon Biologics is a global biosimilars company committed to providing affordable access to high-quality biologic medicines. The company develops and manufactures biosimilar products including insulin analogs for diabetes, monoclonal antibodies for cancer and autoimmune diseases, and other biologic therapies. Biocon’s portfolio includes biosimilars to trastuzumab, bevacizumab, adalimumab, and various insulin products, helping reduce healthcare costs worldwide.